JP2005527615A5 - - Google Patents

Download PDF

Info

Publication number
JP2005527615A5
JP2005527615A5 JP2004506859A JP2004506859A JP2005527615A5 JP 2005527615 A5 JP2005527615 A5 JP 2005527615A5 JP 2004506859 A JP2004506859 A JP 2004506859A JP 2004506859 A JP2004506859 A JP 2004506859A JP 2005527615 A5 JP2005527615 A5 JP 2005527615A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cyclodextrin
biii
acid
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004506859A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005527615A (ja
Filing date
Publication date
Priority claimed from DE10223783A external-priority patent/DE10223783A1/de
Application filed filed Critical
Publication of JP2005527615A publication Critical patent/JP2005527615A/ja
Publication of JP2005527615A5 publication Critical patent/JP2005527615A5/ja
Pending legal-status Critical Current

Links

JP2004506859A 2002-05-29 2003-05-23 ナトリウムチャンネルブロッカーの非経口適用のための新規な製剤 Pending JP2005527615A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10223783A DE10223783A1 (de) 2002-05-29 2002-05-29 Neue Formulierung zur parenteralen Applikation eines Na-Kanal-Blockers
PCT/EP2003/005399 WO2003099336A1 (de) 2002-05-29 2003-05-23 Formulierung zur parenteralen applikation eines na-kanal-blockers

Publications (2)

Publication Number Publication Date
JP2005527615A JP2005527615A (ja) 2005-09-15
JP2005527615A5 true JP2005527615A5 (cg-RX-API-DMAC7.html) 2006-07-13

Family

ID=29432393

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004506859A Pending JP2005527615A (ja) 2002-05-29 2003-05-23 ナトリウムチャンネルブロッカーの非経口適用のための新規な製剤

Country Status (12)

Country Link
EP (1) EP1511517B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005527615A (cg-RX-API-DMAC7.html)
AR (1) AR040134A1 (cg-RX-API-DMAC7.html)
AT (1) ATE373492T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003237664A1 (cg-RX-API-DMAC7.html)
CA (1) CA2487150A1 (cg-RX-API-DMAC7.html)
DE (2) DE10223783A1 (cg-RX-API-DMAC7.html)
ES (1) ES2294295T3 (cg-RX-API-DMAC7.html)
PE (1) PE20040066A1 (cg-RX-API-DMAC7.html)
TW (1) TW200400029A (cg-RX-API-DMAC7.html)
UY (1) UY27823A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003099336A1 (cg-RX-API-DMAC7.html)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4239877C1 (de) * 1992-11-27 1994-03-17 Boehringer Ingelheim Int Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung
DE4313408A1 (de) * 1993-04-23 1994-10-27 Boehringer Mannheim Gmbh Cyclodextrin-Biocid-Komplex
FR2713934B1 (fr) * 1993-12-22 1996-01-12 Commissariat Energie Atomique Utilisation de cyclodextrines aminées pour la solubilisation aqueuse de composés hydrophobes, en particulier de molécules pharmaceutiquement actives.
DE19740110A1 (de) * 1997-09-12 1999-03-18 Boehringer Ingelheim Pharma Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6565880B2 (en) * 2000-07-24 2003-05-20 Boehringer Ingelheim Pharmaceuticals, Inc. Oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea
DE10223784A1 (de) * 2002-05-29 2003-12-11 Boehringer Ingelheim Pharma Neue Formulierung zur parenteralen Applikation von Crobenetine

Similar Documents

Publication Publication Date Title
JP2019131596A5 (cg-RX-API-DMAC7.html)
CA2401424C (en) Alprazolam inclusion complexes and pharmaceutical compositions thereof
US20050250738A1 (en) Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
JP5785175B2 (ja) スルホブチルエーテルシクロデキストリン塩を含有する内水相を有するリポソーム
JP2008526757A5 (cg-RX-API-DMAC7.html)
JP2006514923A5 (cg-RX-API-DMAC7.html)
CN113181110A (zh) 含有防腐的醚化的环糊精衍生物的液体水性药物组合物
JP2020535227A5 (cg-RX-API-DMAC7.html)
KR20140107378A (ko) 브렉스피프라졸 및 치환 베타-시클로덱스트린을 포함하는 약학 제제
JP4384402B2 (ja) デスフルオロピリドンカルボン酸系化合物を含有する水溶液剤およびその粉末化物並びにそれら製造方法
JP2005527615A5 (cg-RX-API-DMAC7.html)
HRP20231337T1 (hr) Vodena formulacija koja sadrži 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]ureu
Granero et al. Promising complexes of acetazolamide for topical ocular administration
JP2006052172A5 (cg-RX-API-DMAC7.html)
JP2011502169A5 (cg-RX-API-DMAC7.html)
JP2005527615A (ja) ナトリウムチャンネルブロッカーの非経口適用のための新規な製剤
JP2011506486A (ja) 医薬組成物
JP2006516279A5 (cg-RX-API-DMAC7.html)
US6828311B2 (en) Formulation for the parenteral application of a sodium channel blocker
US5712260A (en) Estramustine formulations with improved pharmaceutical properties
JP4275394B2 (ja) 注射用シロスタゾール水性製剤
JP5853430B2 (ja) 内服液剤
US8834932B2 (en) Anticoagulant-conjugated carbon nanocapsule, antithrombotic agent containing thereof
RU2021120840A (ru) Составы на основе бранаплама для перорального применения
Praphanwittaya 1.2 Tyrosine kinase inhibitors